Differential effects of thalidomide on angiogenesis and tumor growth in mice.

作者: Andrezza V. Belo , Mônica A. N. D. Ferreira , Adriana A. Bosco , Rosângela D. P. Machado , Silvia P. Andrade

DOI: 10.1023/A:1007114404953

关键词:

摘要: Thalidomide, clinically used as an antiinflammatory and antitumoral drug, inhibited sponge-induced angiogenesis when administered systemically (100 mg/kg−1) in mice. However, it failed to inhibit solid Ehrlich tumor the same mouse strain. We have functional, biochemical histological parameters assess neovascularization fibrovascular tissue infiltration of mice sponge granuloma. The growth detected by development blood flow hemoglobin content extracted from implants showed that thalidomide formation 40%. functional correlated well with study. Thalidomide had no inhibitory effect tumor. detection this selective action using animal strain bearing two different processes, supports hypothesis rather than species specificity, is specific. This approach may be identify specificity other therapeutic agents against distinct angiogenesis-dependent diseases.

参考文章(35)
André Luís Moreira, David Raul Friedlander, Bronya Shif, Gilla Kaplan, David Zagzag, Thalidomide and a thalidomide analogue inhibit endothelial cell proliferation in vitro. Journal of Neuro-oncology. ,vol. 43, pp. 109- 114 ,(1999) , 10.1023/A:1006202700039
R. Pili, A. Passaniti, G. R. Martin, D. S. Grant, R. M. Taylor, P. V. Long, Y. Guo, R. R. Pauly, J. A. Haney, A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Laboratory Investigation. ,vol. 67, pp. 519- 528 ,(1992)
S. P. Andrade, G. P. Lewis, T.-P. D. Fan, Quantitative in-vivo studies on angiogenesis in a rat sponge model. British journal of experimental pathology. ,vol. 68, pp. 755- 766 ,(1987)
Howard A. Fine, William D. Figg, Kurt Jaeckle, Patrick Y. Wen, Athanassios P. Kyritsis, Jay S. Loeffler, Victor A. Levin, Peter M. Black, Richard Kaplan, James M. Pluda, W.K. Alfred Yung, Phase II Trial of the Antiangiogenic Agent Thalidomide in Patients With Recurrent High-Grade Gliomas Journal of Clinical Oncology. ,vol. 18, pp. 708- 715 ,(2000) , 10.1200/JCO.2000.18.4.708
D. A. Walsh, D. -E. Hu, P. I. Mapp, J. M. Polak, D. R. Blake, T. -P. D. Fan, Innervation and neurokinin receptors during angiogenesis in the rat sponge granuloma. Histochemical Journal. ,vol. 28, pp. 759- 769 ,(1996) , 10.1007/BF02272149
Andrew I Minchinton, Karen H Fryer, Karen R Wendt, Kathy A Clow, Malcolm MM Hayes, The effect of thalidomide on experimental tumors and metastases Anti-Cancer Drugs. ,vol. 7, pp. 339- 343 ,(1996) , 10.1097/00001813-199605000-00015
Antonia M. Joussen, Tieno Germann, Bernd Kirchhof, Effect of thalidomide and structurally related compounds on corneal angiogenesis is comparable to their teratological potency Graefes Archive for Clinical and Experimental Ophthalmology. ,vol. 237, pp. 952- 961 ,(1999) , 10.1007/S004170050330
F. E. Kruse, Antonia M. Joussen, Klaus Rohrschneider, Matthias D. Becker, Hans E. V�lcker, Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor. Graefes Archive for Clinical and Experimental Ophthalmology. ,vol. 236, pp. 461- 466 ,(1998) , 10.1007/S004170050106
Kenneth S Bauer, Shannon C Dixon, William D Figg, Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochemical Pharmacology. ,vol. 55, pp. 1827- 1834 ,(1998) , 10.1016/S0006-2952(98)00046-X
Ana Cristina Nogueira, Reinhard Neubert, Hans Helge, Diether Neubert, Thalidomide and the immune system. 3. Simultaneous up- and down-regulation of different integrin receptors on human white blood cells. Life Sciences. ,vol. 55, pp. 77- 92 ,(1994) , 10.1016/0024-3205(94)90099-X